Literature DB >> 29512728

Comparison of the common bacteria in human and mouse tumours using high-throughput sequencing.

Fenghao Zhang1, Mingzheng Zhang1, Yuqing Wang1, Chengjie Li1, Tingtao Chen1.   

Abstract

Evidence has indicated that gut bacteria may serve an important role in cancer development and therapy, while little work has been done to explore the microbial diversity inside tumours. In the present study, high‑throughput sequencing was first used to identify and compare the microbial diversity in human and mouse tumours. Principal component analysis (PCA) and β-diversity indicated a low microbial similarity among mouse artificial tumours (M.AT group), mouse spontaneous tumours (M.T group) and human tumours (H.T group), and Serratia (35.85 vs. 32.64 vs. 73.32%), Pseudomonas (24.10 vs. 16.62 vs. 1.72%) and Ochrobactrum (6.28 vs. 11.08 vs. 11.90%) were identified as dominant bacteria at the genus level. In addition, Venn results indicated 103 common operational taxonomic units (OTUs) in the M.AT, M.T and H.T groups, and only 2 and 1 OTUs belonged to Lactobacillus and Escherichia, respectively, while no OTUs belonging to Salmonella, Bifidobacteria or Clostridium were identified. In the present study, the common bacteria between human and mouse tumours were identified, which may serve as potential strains for bacteriotherapy of cancers.

Entities:  

Mesh:

Year:  2018        PMID: 29512728     DOI: 10.3892/mmr.2018.8689

Source DB:  PubMed          Journal:  Mol Med Rep        ISSN: 1791-2997            Impact factor:   2.952


  2 in total

1.  Evaluation of the potential of chicoric acid as a natural food antioxidant.

Authors:  Xueliang Zhu; Fenghong Huang; Xia Xiang; Min Fan; Tingtao Chen
Journal:  Exp Ther Med       Date:  2018-08-13       Impact factor: 2.447

2.  Evaluation of the inhibitory effects of vaginal microorganisms on sperm motility in vitro.

Authors:  Huan Wang; Tingtao Chen; Yidan Chen; Tao Luo; Buzhen Tan; Houyang Chen; Hongbo Xin
Journal:  Exp Ther Med       Date:  2019-11-22       Impact factor: 2.447

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.